Cancerous inhibitor of protein phosphatase 2A in Parkinson’s disease
Objective: To investigate the expression level of Cancerous Inhibitor of Protein phosphatase 2A (CIP2A) in Parkinson’s disease (PD), and explore the relationship between CIP2A and…The exosomal a-syn filaments can be a novel biomarker of Parkinson’s disease
Objective: This study is aimed to investigate whether the number of exosomes, the amount of total or exosomal a-synuclein (a-syn) filaments in serum can serve as…Lack of sensitivity of full-depth upper gastrointestinal specimens as a prodromal biomarker for synucleinopathy in idiopathic REM sleep behavior disorder
Objective: To examine the phosphorylated alpha-synuclein (pAS) immunohistochemistry of the upper gastrointestinal (GI) tract tissue as a “prodromal” pathologic biomarker for synucleinopathy in idiopathic rapid…A novel likely pathogenic SNCA variant associated with Parkinson’s disease
Objective: To report a novel SNCA likely pathogenic variant. Background: The A53T mutation in the SNCA gene, encoding alpha-synuclein (a-syn), was the first established genetic…Alpha-synuclein preformed fibril (PFF)-triggered synucleinopathy recapitulates neurochemical features of human PD: A PET study in rats
Objective: To investigate longitudinal dopaminergic deficits and similarity to human Parkinson’s disease (PD) using PET imaging in the rat alpha-synuclein (a-syn) preformed fibril (PFF) model.…Quantifying movement to measure Parkinson’s Disease severity and progression in a Phase 2 Study (SPARK)
Objective: To develop and evaluate objective measures of Parkinson’s disease (PD) severity and progression by applying dynamical systems analysis to inertial sensor kinematic data. Background:…Variants in the saposin D domain of prosaposin gene are linked to Parkinson’s disease
Objective: To investigate whether the variants of prosaposin can be linked to Parkinson's disease (PD) [1]. Background: Recent growing investigations have promoted the evidence of…Predicting Longitudinal Atrophy in Parkinson’s Disease using SIR model
Objective: To predict longitudinal brain changes in Parkinson's disease (PD) using an agent-based model. Background: Considerable evidence suggests that α-synuclein(α-syn) behaves in a prion-like fashion,…Morphological changes of retina in patients with Parkinson’s disease and the role of α-synuclein in retinal damage
Objective: To analyze the characteristics of retinal structural changes in patients with PD by the noninvasive technology of OCT. Demonstrate the role of α-syn in pathological changes of…DJ1 and α-Synuclein as CSF biomarkers and gene polymorphisms: association with clinical parameters in Parkinson’s disease
Objective: To analyze the CSF α-Synuclein and DJ1 Biomarkers correlating with SNCA and DJ1 gene polymorphisms and clinical parameters in PD. Background: Currently there is…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 51
- Next Page »